Ezetimibe

證據等級: L5

預測適應症: 4 個

Ezetimibe: From Hypercholesterolemia to Hyperlipoproteinemia

One-Sentence Summary

Ezetimibe is a cholesterol absorption inhibitor globally used to treat hypercholesterolemia and mixed dyslipidemia, though it is not currently registered or marketed in Taiwan. The TxGNN model predicts it may be effective for Hyperlipoproteinemia, with 50 clinical trials and 19 publications currently supporting this direction — though this largely reflects an extension of ezetimibe’s already-established lipid-lowering use rather than a genuinely novel indication.

Quick Overview

Item	Content
Original Indication	Hypercholesterolemia / mixed dyslipidemia (globally approved use; no Taiwan-specific license record in this dataset)
Predicted New Indication	Hyperlipoproteinemia
TxGNN Prediction Score	99.63%
Evidence Level	L1
US Market Status	Not Marketed (Taiwan)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action (MOA) data is flagged as a data gap in this evidence pack. Based on well-established pharmacology, however, ezetimibe selectively inhibits the intestinal Niemann-Pick C1-Like 1 (NPC1L1) transporter, blocking absorption of dietary and biliary cholesterol at the brush border of the small intestine. This reduces delivery of cholesterol to the liver, upregulates LDL receptor expression, and lowers circulating LDL cholesterol (LDL-C) — an effect that is additive when combined with a statin.

Hyperlipoproteinemia is a broad classification of lipid disorders characterized by elevated lipoprotein/LDL-C levels, and it already encompasses conditions (such as hypercholesterolemia and familial hypercholesterolemia) for which ezetimibe’s efficacy is firmly established. As the evidence pack’s own repurposing rationale notes, this prediction reflects “the same mechanism as in familial hypercholesterolemia (NPC1L1 inhibition → reduced intestinal cholesterol absorption → lowered LDL-C)” and represents an existing pharmacological extension rather than a truly novel indication.

Because NPC1L1 inhibition acts directly on the lipid-handling pathway underlying hyperlipoproteinemia, the mechanistic rationale is strong, and this is corroborated by an extensive body of completed Phase 3 trials evaluating ezetimibe (alone or in fixed-dose combinations) across related hypercholesterolemia/dyslipidemia populations.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03884452	Phase 3	Completed	50	Ezetimibe + atorvastatin/simvastatin in homozygous familial hypercholesterolemia; efficacy/safety confirmed
NCT00092573	Phase 3	Completed	576	Fenofibrate + ezetimibe coadministration effective and safe in mixed hyperlipidemia
NCT00701883	Phase 2	Completed	183	Placebo/active-controlled study of MBX-8025 ± atorvastatin in hyperlipidemic patients; supportive comparator data
NCT04929249	Phase 3	Completed	450	“Inclisiran-first” strategy vs usual care in ASCVD with elevated LDL-C; ezetimibe part of background therapy
NCT00652431	Phase 1	Completed	18	PK interaction study of Vytorin (ezetimibe/simvastatin) with niacin extended-release
NCT01984424	Phase 3	Completed	511	Evolocumab vs ezetimibe in statin-intolerant hypercholesterolemic patients
NCT03337308	Phase 3	Completed	382	Bempedoic acid + ezetimibe fixed-dose combination effective/safe vs components and placebo on maximal statin therapy
NCT06005597	Phase 3	Completed	407	Obicetrapib + ezetimibe FDC evaluated in HeFH/ASCVD patients on maximal lipid-lowering therapy
NCT00552097	Phase 3	Completed	720	ENHANCE trial: ezetimibe + high-dose simvastatin vs simvastatin alone on carotid atherosclerosis progression in HeFH
NCT00093899	Phase 3	Completed	611	Ezetimibe/simvastatin + fenofibrate coadministration in mixed hyperlipidemia

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40347969	2025	RCT (TANDEM)	Lancet	Fixed-dose obicetrapib + ezetimibe combination significantly reduces LDL-C
41206969	2026	RCT	JAMA	Oral PCSK9 inhibitor enlicitide evaluated against standard lipid-lowering background including ezetimibe in HeFH
37762244	2023	Review	Int J Mol Sci	Pathophysiology, diagnosis, and treatment of postprandial hyperlipidemia
40682836	2025	Review	Mol Med Rep	Current drug classes targeting hyperlipidemia, including cholesterol absorption inhibitors
35593194	2022	Review	J Cardiovasc Pharmacol Ther	Comprehensive review of PCSK9 inhibitors as add-on to statin/ezetimibe therapy
29219151	2017	Review	Nat Rev Dis Primers	Comprehensive primer on familial hypercholesterolaemia pathophysiology and management
34480646	2021	Review	Curr Cardiol Rep	Global burden and management approaches for familial hypercholesterolemia
33766264	2021	Review	J Am Coll Cardiol	New and emerging LDL-C/ApoB-lowering therapies, positioning ezetimibe among current options
23956253	2013	Consensus Statement	Eur Heart J	EAS consensus on underdiagnosis/undertreatment of FH and screening/treatment guidance
25939291	2015	Review	Cardiol Clin	Overview of familial hypercholesterolemia treatments including statins, ezetimibe, and LDL apheresis

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The predicted indication is supported by an extensive body of completed Phase 3 evidence (L1), but this largely reflects ezetimibe’s already-established global lipid-lowering use rather than a novel mechanism-based hypothesis. Since the drug is not currently registered or marketed in Taiwan, and TFDA label warnings/contraindications and formal MOA documentation are marked as data gaps (one of them Blocking severity), the drug cannot yet clear a full safety pre-assessment (S1).

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) — download and parse from the TFDA website (Blocking gap)
Confirmed mechanism of action documentation via DrugBank API (High-priority gap)
Taiwan registration/import status verification, since the drug is currently unmarketed locally
Drug-drug interaction (DDI) data, currently returning “not found”
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.